Prospective Evaluation of the ReCell Autologous Cell Harvesting Device

Status: open

Prospective Evaluation of the ReCell Autologous Cell Harvesting Device for Specific Compassionate use cases

Treatment for Thermal Burns

Contact Us Or call 251-471-7988

Description

This is a prospective uncontrolled observational study to evaluate clinical outcomes following use of the ReCell Autologous Cell Harvesting Device (ReCell) as an adjunct for closure (re-epithelialization) as a treatment of life-threatening wounds requiring grafting for closure, and associated skin graft donor sites, in patients who lack adequate available skin to harvest for conventional grafting. Treatment with the ReCell device may be performed as part of a single operative procedure, or multiple staged procedures as deemed clinically necessary. Adverse events associated with the use of the ReCell device/cell suspension will be documented. Subjects will be followed for 1 year following ReCell treatment.

Sponsors

This trial is sponsored by Avita Medical.

Providers Associated With This Trial

Principle Investigator

  • Steven KahnView Profile
    Steven Kahn, M.D.Burn/Trauma/Critical Care SurgeonDirector of Arnold Luterman Regional Burn Center; Director of Burn Intensive Care Unit; Assistant Professor of Surgery

Sub Investigators

This link will open in a new tab or window.